Delaying Alzheimer Disease Symptoms With Anti-Inflammatory Drugs
The purpose of this study is to determine whether the anti-inflammatory drug celecoxib can delay the onset of Alzheimer Disease (AD) in people with Age Associated Memory Impairment (AAMI). This study will also evaluate genetic risk and brain structure as potential predictors of mental decline.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Prevention
|Official Title:||Anti-Inflammation in AD: PET Imaging Supplement|
|Study Start Date:||November 2000|
|Primary Completion Date:||November 2005 (Final data collection date for primary outcome measure)|
AD is one of the most common mental disorders of late life. Preliminary studies indicate that anti-inflammatory drugs may attenuate or prevent AD symptoms, but efficacy trials are needed.
Participants in this study will be randomly assigned to receive either celecoxib or placebo for 18 months. Participants will undergo positron emission tomography (PET) and magnetic resonance imaging (MRI) scans of the brain. Routine laboratory blood tests, cognitive tests, and an electrocardiogram (ECG) will be performed. Participants will also be screened for Parkinson disease. Follow-up testing will be conducted at specific intervals following the study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00065169
|United States, California|
|UCLA Neuropsychiatric Institute|
|Los Angeles, California, United States, 90024|